PPARG and obesity disorder: Previous studies reported that mice treated with PPARγ partial antagonists such as SR202, GW9662, or BADGE showed decreased TG content in WAT, liver and skeletal muscle, decreased adipocyte size, and increased resistance to HFD-induced obesity (Anghel & Wahli 2007).